Immutep (IMMP)
NASDAQ:IMMP
Want to see IMMP full AI Analyst Report?
IMMP Stock Chart & Stats
$2.04
-$0.05(-2.44%)
At close: 4:00 PM EST
$2.04
-$0.05(-2.44%)
Day’s Range― - ―
52-Week Range$0.29 - $3.53
Previous CloseN/A
Volume50.42K
Average Volume (3M)1.22M
Market Cap
$49.97M
Enterprise Value$7.52M
Total Cash (Recent Filing)$99.13M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Sep 02, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding147,372,130
10 Day Avg. Volume1,165,747
30 Day Avg. Volume1,218,069
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit-0.10
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$19.00M
Bulls Say, Bears Say
Bulls Say
Orphan Drug Designation For Efti In Soft Tissue SarcomaOrphan Drug status provides regulatory incentives, fee waivers and potential market exclusivity that materially lower development hurdles and costs for a niche indication. This creates a durable, clearer pathway to a late-stage neoadjuvant program and enhances long-term commercial optionality for efti.
First-in-class IMP761 Shows Positive Phase I ProgressIMP761 is a novel LAG-3 agonist with demonstrated safety and durable pharmacology in Phase I, progressing to multiple ascending doses and presenting data at EULAR. As a potential first-in-class therapy for autoimmune indications, it offers structural upside across large markets if later-stage trials confirm efficacy.
Material Cash Position And Partner Upfront Extend RunwayA sizeable cash balance plus a recent $20m upfront reduces near-term financing pressure, funds ongoing trials and the TACTI-004 wind-down, and preserves strategic flexibility. This materially lowers short-term dilution risk and supports program reshaping over the coming quarters.
Bears Say
Phase III TACTI-004 Halted After Futility ReviewStopping a pivotal NSCLC trial is a major adverse structural outcome: it reduces the commercial prospects of efti in a large oncology market, forces strategic reallocation of development resources, and diminishes probability of a high-value approval, raising long-term program risk and partner uncertainty.
Persistent Negative Margins And Weak Cash GenerationChronic negative gross, EBIT and net margins alongside negative operating and free cash flow limit Immutep’s ability to self-fund development. Sustained losses increase reliance on partner payments or fundraising, which can dilute shareholders and constrain strategic independence over the medium term.
Nasdaq Minimum Bid-price Non-compliance NoticeA formal bid-price deficiency raises the risk of Nasdaq delisting if not corrected, which would reduce U.S. investor access and liquidity. This structural compliance risk can complicate future U.S. fundraises, partnerships and investor relations until resolved.
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $0.29 and its highest was $3.53 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $49.97M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Sep 02, 2026 which is in 87 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Feb 24, 2026. The company reported -$0.217 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.02.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Overvalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.03.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.217 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went down -0.357%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.87%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.32% Other Institutional Investors
99.17% Public Companies and
Individual Investors